Table 2.

Contemporary series of systemic therapy (temozolomide or bevacizumab) and radiotherapy in single (SRS) or multi-fraction (FSRT) for recurrent high-grade gliomas.

Author	Year	N	Therapeutic approach	Median fraction number, prescription dose	Median OS after reRT (months)	Toxicity
Gutin et al. [18]	2009	25	FSRS + BEV	5 fx, 30 Gy	12.5	RTOG G3 = 1 (hemorrhage); G4 3 (1 bowel perforation; 1 wound dehiscence; 1 GI bleed)
Torcuator et al. [45]	2010	23	SRS/FSRT +BEV	SRS 18–20 Gy FSRT 6fx, 36 Gy	7.2	Not reported
Minniti et al. [21]	2011	36	FSRT + TMZ	15 fx, 37.5 Gy	9.7	Neurologic deterioration 3
Cuneo et al. [28].	2012	63	SRS/FSRT ± BEV	SRS 18 Gy FSRT 5 fx, 25 Gy	11	RTOG G3 = 11%; RN 10%
Niyazi et al. [31]	2012	30	FSRT +/− BEV	18 fx, 36 Gy	Not reached	RTOG G3 = 1; G4 = 1 (wound dehiscence); 2 RN
Park et al. [27]	2012	11	SRS + BEV	1 fx, 16 Gy	18	RTOG G3 = 1
Cabrera et al. [26]	2013	15	SRS/FSRT + BEV	SRS 18 or 24 Gy FSRT 5 fx, 25 Gy	13	RTOG G3 = 1
Greenspoon et al. [46]	2014	31	SRS + TMZ	5 fx, 25–35 Gy	9	RN RTOG G3 = 3, G4 = 1

ReRT: Re-irradiation, SRS: radiosurgery, FSRT: fractionated stereotactic radiotherapy (multisession radiosurgery), RTOG: radiation therapy oncology group, G: toxicity grade, NA: not available, RN: Radionecrosis, fx: fraction(s).